Joseph Hull Net Worth

The estimated Net Worth of Joseph Stanley Hull is at least 745 千$ dollars as of 5 August 2019. Mr. Hull owns over 800 units of Palatin Technologies stock worth over 744,743$ and over the last 19 years he sold PTN stock worth over 0$. In addition, he makes 0$ as Independent Director at Palatin Technologies.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Hull PTN stock SEC Form 4 insiders trading

Joseph has made over 7 trades of the Palatin Technologies stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 800 units of PTN stock worth 624$ on 5 August 2019.

The largest trade he's ever made was exercising 20,000 units of Palatin Technologies stock on 9 June 2016 worth over 28,600$. On average, Joseph trades about 1,976 units every 83 days since 2005. As of 5 August 2019 he still owns at least 520,799 units of Palatin Technologies stock.

You can see the complete history of Mr. Hull stock trades at the bottom of the page.

Joseph Hull biography

Joseph Stanley Hull serves as Independent Director of the Company. Mr. Hull has over three decades of experience in the field of sales, marketing and drug development. Mr. Hull joined GlaxoSmithKline, a research-based pharmaceutical company, in October 1987 and retired as Senior Vice President, Pharmaceuticals – North America in May 2010. Mr. Hull was responsible for all commercial activities including sales, marketing, sales training and office operations. Previously Mr. Hull served in the R&D organization of Glaxo Wellcome as Vice President and Worldwide Director of Therapeutic Development and Product Strategy – Neurology and Psychiatry. Prior to his service in the R&D organization he was Vice President of Marketing – Infectious Diseases and Gastroenterology for Glaxo Wellcome-U.S. Mr. Hull started his career in the pharmaceutical industry with SmithKline and French Laboratories in 1978. Mr. Hull received his B.S. in business administration from the University of North Carolina at Greensboro.

How old is Joseph Hull?

Joseph Hull is 67, he's been the Independent Director of Palatin Technologies since 2005. There are 2 older and 8 younger executives at Palatin Technologies. The oldest executive at Palatin Technologies Inc. is Robert deVeer, 74, who is the Independent Director.

What's Joseph Hull's mailing address?

Joseph's mailing address filed with the SEC is PALATIN TECHNOLOGIES INCORPORATED, 4B CEDAR BROOK DRIVE, CRANBURY, NJ, 08512.

Insiders trading at Palatin Technologies

Over the last 22 years, insiders at Palatin Technologies have traded over 3,929,269$ worth of Palatin Technologies stock and bought 390,692 units worth 374,235$ . The most active insiders traders include Austin W & Greenhouse David...、Partners L P/Ilbiotechnolog...、Carl Spana. On average, Palatin Technologies executives and independent directors trade stock every 76 days with the average trade being worth of 128,497$. The most recent stock trade was executed by Stephen T Wills on 1 August 2024, trading 4,999 units of PTN stock currently worth 8,298$.

What does Palatin Technologies do?

palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy

Complete history of Mr. Hull stock trades at Palatin Technologies

Palatin Technologies executives and stock owners

Palatin Technologies executives and other stock owners filed with the SEC include:

• Carl Spana,
  President, Chief Executive Officer, Director
• stephen Wills,
  Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary
• Dr. Carl Spana Ph.D.,
  Co-Founder, Pres, CEO & Director
• Stephen T. Wills CPA, CPA, MST,
  CFO, COO, Exec. VP, Treasurer & Sec.
• Angela Rossetti,
  Independent Director
• Arlene Morris,
  Independent Director
• Anthony Manning,
  Independent Director
• Joseph Hull,
  Independent Director
• Alan Dunton,
  Independent Director
• Robert deVeer,
  Independent Director
• John Prendergast,
  Independent Chairman of the Board
• Robert Jordan,
  Sr. VP of Program Operations
• John Dodd Ph.D.,
  Sr. VP of Preclinical Devel.
• James E. Hattersley,
  Sr. VP of Bus. Devel.
• Dr. Michael B. Raizman M.D.,
  Chief Medical Officer
• Stephen A. Slusher Esq.,
  Chief Legal Officer
• Burns McClellan,
  VP of Investor Relations
• Zola P Horovitz,
  Director
• Robert I Taber,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Austin W & Greenhouse David...,
  10% owner
• Errol B Desouza,
  Director
• Trevor Hallam,
  Exec. VP Res. & Dev.
• Perry B Molinoff,
  Exec. VP Research and Devel.
• Investments Lpproquest Asso...,
  
• Joseph Edelman,
  10% owner